Bio Medica Laboratories Limited
SMEBMLL • NSE
Issue details
Price band
₹132 - ₹139
Lot size
1,000 shares
Issue size
₹52 Cr
Min. investment
₹1,39,000
Registrar
Skyline Financial Services
Grey market premium
Save your family's PANs once and check allotment for everyone the moment results are out.
Sign in with a mobile OTP. It takes 20 seconds.
IPO Timeline
Open
21 May
Close
25 May
Allotment
26 May
Listing
29 May
- Refunds & demat credit
- 27 May 2026
- Mandate end
- 9 Jun 2026
We calculate these dates from the allotment and close dates, so please treat them as indicative.
Application size
| Category | Minimum | Maximum |
|---|---|---|
| Retail | 1,000shares 1 lot · ₹1,39,000 | 1,000shares 1 lot · ₹1,39,000 |
| HNI | 2,000shares 2 lots · ₹2,78,000 | No limit funds permitting |
Based on the upper price band of ₹139 and a lot of 1,000 shares.
Issue structure
Face value
₹10 per share
Issue type
Bookbuilding IPO
Sale type
Fresh capital cum OFS
Fresh issue
₹45 Cr
32,06,000 shares
Offer for sale
₹5 Cr
3,77,000 shares
Shares pre-issue
91,80,001
Shares post-issue
1,25,75,001
Reservation
- QIB
- 36,000
- NII
- 17,55,000
- Retail
- 17,92,000
Valuation & ratios
| Metric | Pre-IPO | Post-IPO |
|---|---|---|
| EPS | 10.67 | 10.33 |
| P/E | 13.03 | 13.45 |
| Market cap | ₹127.60 Cr. | ₹145.62 Cr |
| KPI | Nov 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 54.41% | 99.59% |
| ROCE | 23.22% | 48.20% |
| Debt/Equity | 2.23 | 1.02 |
| RoNW | 54.41% | 99.59% |
| PAT Margin | 30.35% | 25.64% |
| EBITDA Margin | 47.11% | 39.83% |
| NAV | 18.64 | 16.05 |
| Price to Book Value | — | 8.66 |
Financials
| Metric | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Total income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit after tax | 8.66 | 9.79 | 2.5 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.7 |
| Net worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Reserves & surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Figures in ₹ crore, as reported by the company in its offer document.
Objects of the issue
- 1.Repayment of loan₹6.5 Cr
- 2.Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises₹28.5 Cr
- 3.General Corporate Purposes₹7.05 Cr
- 4.Issue Expense₹5.14 Cr
What the company says it intends to do with the money raised.
Recent comparable IPOs
| Company | Issue price | P/E | Listing close | Listing gain |
|---|---|---|---|---|
| Goldline Pharmaceutical Ltd.SME | ₹43 | 10.47 | ₹56.77 | +32.02% |
| Speciality Medicines Ltd.SME | ₹124 | 9.27 | ₹125.90 | +1.53% |
| Accretion Nutraveda Ltd.SME | ₹129 | 26.27 | ₹191.20 | +48.22% |
| KRM Ayurveda Ltd.SME | ₹135 | 17.32 | ₹180.70 | +33.85% |
| Curis Lifesciences Ltd.SME | ₹128 | 12.44 | ₹141.00 | +10.16% |
| Aptus Pharma Ltd.SME | ₹70 | 11.29 | ₹84.84 | +21.20% |
| Asston Pharmaceuticals Ltd.SME | ₹123 | 17.83 | ₹124.95 | +1.59% |
| Influx Healthtech Ltd.SME | ₹96 | 13.04 | ₹126.20 | +31.46% |
| Astonea Labs Ltd.SME | ₹135 | 27.36 | ₹135.65 | +0.48% |
| Sai Parenteral's Ltd.Mainboard | ₹392 | 72.19 | ₹405.70 | +3.49% |
| Corona Remedies Ltd.Mainboard | ₹1062 | 43.47 | ₹1,438.40 | +35.44% |
| Rubicon Research Ltd.Mainboard | ₹485 | 55.75 | ₹628.20 | +29.53% |
| Amanta Healthcare Ltd.Mainboard | ₹126 | 34.59 | ₹141.75 | +12.50% |
| Anlon Healthcare Ltd.Mainboard | ₹91 | 17.67 | ₹91.73 | +0.80% |
Past listing performance of comparable issues. This is not a forecast: listing gains vary widely and can turn negative.
Issue fundamentals compiled from the company's offer document via Chittorgarh, last read 27 Sep 2026. Always verify against the RHP before applying.